Needham Keeps a Buy Rating on Iterum Therapeutics (ITRM)

Needham analyst Alan Carr maintained a Buy rating on Iterum Therapeutics (ITRMResearch Report) today and set a price target of $20.00. The company’s shares closed last Monday at $4.85.

According to TipRanks.com, Carr is a 1-star analyst with an average return of -0.2% and a 41.5% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iterum Therapeutics with a $18.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.30 and a one-year low of $1.68. Currently, Iterum Therapeutics has an average volume of 61.41K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents.